What is the place of empirical proton pump inhibitor testing in the diagnosis of gastroesophageal reflux disease? (Description, duration, and dosage)

被引:5
|
作者
Vardar, Rukiye [1 ]
Keskin, Muharrem [2 ]
机构
[1] Ege Univ, Dept Gastroenterol, Sch Med, Izmir, Turkey
[2] Necmettin Erbakan Univ, Dept Gastroenterol, Sch Med, Konya, Turkey
关键词
Empirical PPI test; GERD; PPI trial test; NONCARDIAC CHEST-PAIN; HIGH-DOSE RABEPRAZOLE; OMEPRAZOLE TEST; PRIMARY-CARE; NEGATIVE PATIENTS; SYMPTOM RESPONSE; CROSSOVER TRIAL; DOUBLE-BLIND; LANSOPRAZOLE; ENDOSCOPY;
D O I
10.5152/tjg.2017.05
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Empirical acid suppression tests that are performed with proton pump inhibitors (PPI) are used to detect both the presence of acid-related gastrointestinal symptoms and gastroesophageal reflux disease (GERD). In comparison to other diagnostic methods, it is non-invasive, easily applicable, and cost-effective in the diagnosis of GERD. In addition to typical reflux symptoms, it can also be used for diagnostic purposes in patients with non-cardiac chest pain (NCCP). If the symptom response is 50% and above when obtained using the PPI test in patients with NCCP, it can be considered as positive and the treatment should be continued sensitivity of the PPI test in patients with typical symptoms of GERD is 27%-89%, while its specificity is 35%-83%. Although there are differences related to the duration and dosage of the PPI test, a significant difference has not been found according to the type of PPI. When PPI test sensitivity and specificity were calculated by cumulatively evaluating the data regarding the PPI test in the literature, a sensitivity of 82.3% and specificity of 51.5% was obtained. It has been found that high doses of PPI were mostly used in studies, and the duration of the median test was 14 days. As a result, the sensitivity of PPI trial test is good, but the specificity is low in the diagnosis of GERD in patients with typical reflux symptoms.
引用
收藏
页码:S12 / S15
页数:4
相关论文
共 50 条
  • [41] Comparison of the efficiency of two different proton pump inhibitor formula in treatment of patients with atypical gastroesophageal reflux disease: a prospective randomized study
    Lin, Xi-Hsuan
    Luo, Jiing-Chyuan
    Ting, Po-Hsiang
    Chang, Tien-En
    Huang, Yi-Hsiang
    Hou, Ming-Chih
    Lee, Fa-Yauh
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2020, 35 (12) : 2096 - 2102
  • [42] Vonoprazan versus proton-pump inhibitors for healing gastroesophageal reflux disease: A systematic review
    Miyazaki, Hirota
    Igarashi, Ataru
    Takeuchi, Toshihisa
    Teng, Lida
    Uda, Akihito
    Deguchi, Hisato
    Higuchi, Kazuhide
    Tango, Toshiro
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 (08) : 1316 - 1328
  • [43] Comparative Safety and Efficacy of Proton Pump Inhibitors in Paediatric Gastroesophageal Reflux Disease
    Kierkus, Jaroslaw
    Oracz, Grzegorz
    Korczowski, Bartosz
    Szymanska, Edyta
    Wiernicka, Anna
    Woynarowski, Marek
    DRUG SAFETY, 2014, 37 (05) : 309 - 316
  • [44] Management of gastroesophageal reflux disease that does not respond well to proton pump inhibitors
    Hershcovici, Tiberiu
    Fass, Ronnie
    CURRENT OPINION IN GASTROENTEROLOGY, 2010, 26 (04) : 367 - 378
  • [45] Comparative Safety and Efficacy of Proton Pump Inhibitors in Paediatric Gastroesophageal Reflux Disease
    Jaroslaw Kierkus
    Grzegorz Oracz
    Bartosz Korczowski
    Edyta Szymanska
    Anna Wiernicka
    Marek Woynarowski
    Drug Safety, 2014, 37 : 309 - 316
  • [46] Efficacy and Safety of Proton Pump Inhibitors in the Management of Pediatric Gastroesophageal Reflux Disease
    Tjon, James A.
    Pe, Michael
    Soscia, Joanna
    Mahant, Sanjay
    PHARMACOTHERAPY, 2013, 33 (09): : 956 - 971
  • [47] Gastroesophageal reflux in children: Pathogenesis, prevalence, diagnosis, and role of proton pump inhibitors in treatment
    Gold B.D.
    Freston J.W.
    Pediatric Drugs, 2002, 4 (10) : 673 - 685
  • [48] The Impact of Proton Pump Inhibitor Compliance on Health-Care Resource Utilization and Costs in Patients with Gastroesophageal Reflux Disease
    Gosselin, Antoine
    Luo, Roger
    Lohoues, Herve
    Toy, Edmond
    Lewis, Barbara
    Crawley, Joseph
    Duh, Mei Sheng
    VALUE IN HEALTH, 2009, 12 (01) : 34 - 39
  • [49] A Review of Histamine-2 Receptor Antagonist and Proton Pump Inhibitor Therapy for Gastroesophageal Reflux Disease in Neonates and Infants
    Tan, Jason
    Jeffries, Sonia
    Carr, Roxane
    PEDIATRIC DRUGS, 2023, 25 (05) : 557 - 576
  • [50] Multimodality evaluation of patients with gastroesophageal reflux disease symptoms who have failed empiric proton pump inhibitor therapy
    Galindo, G.
    Vassalle, J.
    Marcus, S. N.
    Triadafilopoulos, G.
    DISEASES OF THE ESOPHAGUS, 2013, 26 (05) : 443 - 450